These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27144829)

  • 21. Inhibition of DNA-repair genes Ercc1 and Mgmt enhances temozolomide efficacy in gliomas treatment: a pre-clinical study.
    Boccard SG; Marand SV; Geraci S; Pycroft L; Berger FR; Pelletier LA
    Oncotarget; 2015 Oct; 6(30):29456-68. PubMed ID: 26336131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiation-induced extracellular vesicle (EV) release of miR-603 promotes IGF1-mediated stem cell state in glioblastomas.
    Ramakrishnan V; Xu B; Akers J; Nguyen T; Ma J; Dhawan S; Ning J; Mao Y; Hua W; Kokkoli E; Furnari F; Carter BS; Chen CC
    EBioMedicine; 2020 May; 55():102736. PubMed ID: 32361246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BACH1 Promotes Temozolomide Resistance in Glioblastoma through Antagonizing the Function of p53.
    Nie E; Jin X; Wu W; Yu T; Zhou X; Zhi T; Shi Z; Zhang J; Liu N; You Y
    Sci Rep; 2016 Dec; 6():39743. PubMed ID: 28000777
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide.
    Tso JL; Yang S; Menjivar JC; Yamada K; Zhang Y; Hong I; Bui Y; Stream A; McBride WH; Liau LM; Nelson SF; Cloughesy TF; Yong WH; Lai A; Tso CL
    Mol Cancer; 2015 Nov; 14():189. PubMed ID: 26546412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy.
    Jiang G; Wei ZP; Pei DS; Xin Y; Liu YQ; Zheng JN
    Biochem Biophys Res Commun; 2011 Mar; 406(3):311-4. PubMed ID: 21329652
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients.
    Brandes AA; Franceschi E; Tosoni A; Blatt V; Pession A; Tallini G; Bertorelle R; Bartolini S; Calbucci F; Andreoli A; Frezza G; Leonardi M; Spagnolli F; Ermani M
    J Clin Oncol; 2008 May; 26(13):2192-7. PubMed ID: 18445844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Core pathway mutations induce de-differentiation of murine astrocytes into glioblastoma stem cells that are sensitive to radiation but resistant to temozolomide.
    Schmid RS; Simon JM; Vitucci M; McNeill RS; Bash RE; Werneke AM; Huey L; White KK; Ewend MG; Wu J; Miller CR
    Neuro Oncol; 2016 Jul; 18(7):962-73. PubMed ID: 26826202
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HIF-1α inhibition sensitizes pituitary adenoma cells to temozolomide by regulating MGMT expression.
    Chen W; Xiao Z; Zhao Y; Huang L; Du G
    Oncol Rep; 2013 Nov; 30(5):2495-501. PubMed ID: 23970362
    [TBL] [Abstract][Full Text] [Related]  

  • 30. O6-methylguanine-DNA methyltransferase is downregulated in transformed astrocyte cells: implications for anti-glioma therapies.
    Sasai K; Akagi T; Aoyanagi E; Tabu K; Kaneko S; Tanaka S
    Mol Cancer; 2007 Jun; 6():36. PubMed ID: 17547775
    [TBL] [Abstract][Full Text] [Related]  

  • 31. O6-Methylguanine-DNA-methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry.
    Buccoliero AM; Castiglione F; Rossi Degl'Innocenti D; Paglierani M; Maio V; Gheri CF; Garbini F; Moncini D; Taddei A; Sardi I; Sanzo M; Giordano F; Mussa F; Genitori L; Taddei GL
    J Chemother; 2008 Apr; 20(2):263-8. PubMed ID: 18467255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Exclusion of histiocytes/endothelial cells and using endothelial cells as internal reference are crucial for interpretation of MGMT immunohistochemistry in glioblastoma.
    Hsu CY; Lin SC; Ho HL; Chang-Chien YC; Hsu SP; Yen YS; Chen MH; Guo WY; Ho DM
    Am J Surg Pathol; 2013 Feb; 37(2):264-71. PubMed ID: 23282970
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Strategy for studying gene methylation: the example of MGMT].
    Fina F; Nanni-Metellus I; Courdy C; Figarella-Branger D; Martin PM; Ouafik L
    Ann Pathol; 2009 Nov; 29 Spec No 1():S37-9. PubMed ID: 19887248
    [No Abstract]   [Full Text] [Related]  

  • 34. MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial.
    Weller M; Tabatabai G; Kästner B; Felsberg J; Steinbach JP; Wick A; Schnell O; Hau P; Herrlinger U; Sabel MC; Wirsching HG; Ketter R; Bähr O; Platten M; Tonn JC; Schlegel U; Marosi C; Goldbrunner R; Stupp R; Homicsko K; Pichler J; Nikkhah G; Meixensberger J; Vajkoczy P; Kollias S; Hüsing J; Reifenberger G; Wick W;
    Clin Cancer Res; 2015 May; 21(9):2057-64. PubMed ID: 25655102
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gain of function of mutant TP53 in glioblastoma: prognosis and response to temozolomide.
    Wang X; Chen JX; Liu JP; You C; Liu YH; Mao Q
    Ann Surg Oncol; 2014 Apr; 21(4):1337-44. PubMed ID: 24248532
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recurrent Glioblastomas Reveal Molecular Subtypes Associated with Mechanistic Implications of Drug-Resistance.
    Kwon SM; Kang SH; Park CK; Jung S; Park ES; Lee JS; Kim SH; Woo HG
    PLoS One; 2015; 10(10):e0140528. PubMed ID: 26466313
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PLEKHG5 regulates autophagy, survival and MGMT expression in U251-MG glioblastoma cells.
    Witte KE; Slotta C; Lütkemeyer M; Kitke A; Coras R; Simon M; Kaltschmidt C; Kaltschmidt B
    Sci Rep; 2020 Dec; 10(1):21858. PubMed ID: 33318498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cilengitide in glioblastoma: when did it fail?
    Chinot OL
    Lancet Oncol; 2014 Sep; 15(10):1044-5. PubMed ID: 25163907
    [No Abstract]   [Full Text] [Related]  

  • 39. Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting.
    Huang Z; Cheng L; Guryanova OA; Wu Q; Bao S
    Protein Cell; 2010 Jul; 1(7):638-55. PubMed ID: 21203936
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools.
    Valdebenito S; D'Amico D; Eugenin E
    Cancer Rep (Hoboken); 2019 Dec; 2(6):e1220. PubMed ID: 32729241
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.